Oragenics, Inc. (OGEN)
| Previous close | 1.1300 |
| Open | 1.1600 |
| Bid | 1.1600 x 1000 |
| Ask | 1.1900 x 800 |
| Day's range | 1.1750 - 1.2200 |
| 52-week range | 1.0100 - 7.7400 |
| Volume | |
| Avg. volume | 98,864 |
| Market cap | 5.265M |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.1800 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
SARASOTA, Fla., April 01, 2024--Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve t
- Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
SARASOTA, Fla., March 18, 2024--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 i
Insider Monkey15 Highest Quality Probiotics For Gut Health
In this article, we will be taking a look at the 15 highest quality probiotics for gut health. If you do not want to learn about the global probiotic market, head straight to the 5 Highest Quality Probiotics For Gut Health. Achieving optimal gut health is paramount for overall well-being, and selecting the highest quality […]
